Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031
상품코드:1812606
리서치사:Kalorama Information
발행일:2025년 09월
페이지 정보:영문 260 Pages
라이선스 & 가격 (부가세 별도)
한글목차
"진단학 분야 바이오마커 시장 - 세계 전략적 인사이트 및 예측(-2031년)"에서는 세계 임상 진단용 바이오마커 시장을 종합적으로 분석하고 2022년부터 2031년까지의 예측을 게재하고 있습니다. 본 보고서는 감염, 암, 심혈관질환, 일반 임상화학분석, 신경질환, 자가면역질환, 당뇨병, 대사 이상, 불임, 임신, 신장질환, 유전질환, 갑상선질환 등 7가지 주요 제품 카테고리에서 질환의 발견, 치료법 선택, 질환 모니터링, 치료 효과 평가에 사용되는 진단약 및 검사에 대해 연구하고 있습니다.
미국, 유럽, 중국, 중국, 인도, 일본 예측과 함께 각 카테고리 및 주요 하위 그룹별 세계 및 지역별 판매 데이터를 제공합니다. 시장 가치는 모두 바이오마커 관련 시약, 검사 키트, 소모품에 대한 최종사용자의 지출을 반영한 것이며, 진단 장비의 가치는 포함되지 않았습니다. 이 데이터는 제조업체, 실험실 관계자, 업계 전문가에 대한 광범위한 1차 인터뷰와 정부 통계, 산업 협회, 기업 제출 서류, Kalorama 간행물 등의 2차 정보를 바탕으로 작성되었습니다.
인구 고령화, 표적 치료제 도입, 진단 검사 시장 확대, 질량분석, 차세대 시퀀싱, 바이오인포매틱스 등 기술 발전 등 주요 산업 촉진요인을 조사하고 있습니다. 맞춤의료와 정밀의료에서 바이오마커의 역할, 약리유전체학 동향, 자동화, 리베이트, 혁신 파이프라인 등도 다루고 있습니다. 심층적인 경쟁 분석은 주요 체외진단 의약품 기업 및 바이오마커 전문 기업을 프로파일링하고, 제품화 된 제품, 새로운 기술, 시장 포지셔닝에 초점을 맞추고 있습니다.
상세한 세분화, 시장 동향, 전략적 인사이트를 통해 "진단학 분야 바이오마커 시장 - 2031년까지 세계 전략적 인사이트 및 예측(종양 마커, 신장질환 마커, 유전질환 마커, 심장 마커, 신경학 마커, 자가면역질환, 감염질환, 기타 마커)"은 바이오마커 분야에서 경쟁하는 기업이나 이 고성장 시장에 진출하고자 하는 기업에게 필수적인 자료가 될 것입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 환경과 분석
개요
인구통계 패턴
총인구
65세 이상 인구
세계의 헬스케어 동향
의료비
병원
의사
환자 활동
입원
외과수술
외래 진료
세계 경제 기후
바이오마커 기술
바이오마커 분석에서 AI와 머신러닝의 역할 상승
바이오마커 시장 분석
주요 시장 동향
바이오마커 제품 시장
지리적 시장
제4장 감염증 바이오마커
개요
감염증 바이오마커 기술
감염증 주요 바이오마커
호흡기질환
COVID-19
폐렴
인플루엔자
A군 연쇄구균 감염증
결핵
기타 호흡기 감염증
의료 관련 감염증(HAI)
클로스트리디오이데스 디피실(C. diff)
패혈증
황색포도구균
엔테로코커스
기타 의료 관련 감염증
간염
HIV
성감염증(STD)
인유두종바이러스(HPV)
클라미디아/임질(CT/NG)
트리코모나스증
단순포진바이러스(HSV-1 및 HSV-2)
기타 성감염증
매독
귀두염
연성하감
전염성 연부종
골반내 염증성 질환(PID)
음슬
옴
질염
토치
기타 감염증
말라리아
라임병
파일로리균
뎅기열
기타 모든 질환 바이오마커
샤가스병
시크로스포라증
낭충증
에볼라
한타바이러스
백선
웨스트 나일 바이러스(WNV)
지카바이러스
기타 감염증 바이오마커 판매
시장 분석
바이오마커 제품 공급업체
제5장 암 바이오마커
개요
암의 중요한 바이오마커
최근 동향
약물 유전자 적합성 예측 바이오마커 검사
약물 진단 검사
정밀 암 치료
액체 생검에 기반한 비침습성 암 분자진단
순환종양세포(CTC) 검사
엑소좀 시퀀싱
차세대 시퀀싱 검사
시장 분석
바이오마커 제품 공급업체
제6장 심혈관 바이오마커
개요
심혈관질환 주요 바이오마커
최근 동향
고감도 트로포닌(hs-cTn)
나트륨 이뇨 펩타이드(BNP/NT-proBNP)
염증 바이오마커
대사 및 지질 관련 바이오마커
신흥 바이오마커와 멀티오믹스 접근법
AI와 머신러닝의 통합
시장 분석
바이오마커 제품 공급업체
제7장 임상화학 바이오마커
개요
임상화학의 주요 바이오마커
전해질과 혈액가스
소변 검사
워크스테이션 면역측정 검사
갑상선 검사
생식 능력과 기타 바이오마커
최근 동향
시장 분석
바이오마커 제품 공급업체
제8장 신경학적 바이오마커
개요
신경질환 주요 바이오마커
최근 동향
알츠하이머병 혈액 검사의 혁명
외상성 뇌손상(TBI) 바이오마커의 진보
디지털 뉴로 바이오마커와 AI/ML의 통합
기타 신경질환 바이오마커
멀티오믹스와 액체 생검 접근법
시장 분석
바이오마커 제품 공급업체
제9장 자가면역 바이오마커
개요
자가면역질환 주요 바이오마커
최근 동향
기존 자가항체를 넘어 확장
질환 진행과 치료 반응을 예측하기 위한 바이오마커
시장 분석
바이오마커 제품 공급업체
제10장 기타 바이오마커
개요
기타 질환의 중요한 바이오마커
당뇨병과 대사 바이오마커
임신과 생식에 관한 바이오마커
신장질환
유전성 질환
낭포성섬유증
다운증후군
겸상 적혈구증
고셔병
가족성 고콜레스테롤혈증
근 디스트로피
혈우병
폰빌레브란트병
신경섬유종증
다낭성 신장질환
척수성 근위축증
클라인펠터증후군
카나반병
뇌성마비
안젤만증후군(AS)
기타 유전성 질환
갑상선 질병
기타 모든 바이오마커
골질환 바이오마커
소화관 바이오마커
호흡기 바이오마커
분변 칼프로텍틴
시장 분석
제11장 기업 개요
Abbott Diagnostics
Asuragen(Bio-Techne)
Becton Dickinson, and Company
Bio-Rad Laboratories
Biocartis
Biodesix
bioMerieux
Biotheranostics, Inc.(Hologic)
Danaher Corporation
DiaSorin Group
Exact Sciences
Exosome Diagnostics(Bio-Techne)
Illumina
Myriad Genetics
QuidelOrtho
Qiagen
Roche Diagnostics
Siemens Healthineers
Sysmex Inostics
Thermo Fisher Scientific
KSM
영문 목차
영문목차
Kalorama Information's "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031" provides a comprehensive analysis of the worldwide clinical diagnostic biomarker market, with forecasts from 2022 through 2031. The report examines diagnostic substances and tests used for disease detection, therapy selection, disease monitoring, and evaluation of treatment effectiveness across seven major product categories: infectious diseases, cancer, cardiovascular diseases, general clinical chemistry analytes, neurological conditions, autoimmune conditions, and other conditions such as diabetes, metabolic disorders, fertility, pregnancy, kidney disorders, inherited diseases, and thyroid conditions.
Global and regional sales data-along with projections for the U.S., Europe, China, India, and Japan-are provided for each category and major subgroup. All market values reflect end-user spending on biomarker-related reagents, test kits, and consumables, excluding the value of diagnostic instruments. Data are compiled from extensive primary interviews with manufacturers, laboratory professionals, and industry experts, as well as secondary sources including government statistics, trade associations, company filings, and Kalorama publications.
The report explores key industry drivers such as aging populations, targeted therapy adoption, diagnostic test market expansion, and advances in technologies including mass spectrometry, next-generation sequencing, and bioinformatics. Coverage includes the role of biomarkers in personalized and precision medicine, trends in pharmacogenomics, automation, reimbursement, and innovation pipelines. Detailed competitive analysis profiles leading IVD companies and specialized biomarker firms, highlighting commercialized products, emerging technologies, and market positioning.
With in-depth segmentation, market trends, and strategic insights, "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers)" serves as an essential resource for companies competing in the biomarker space or seeking to enter this high-growth market.
Table of Contents
Chapter 1: Introduction
About Kalorama Information
Report Coverage
Methodology
Sources of Information
Chapter 2: Executive Summary
Table 2-1: Global Biomarker Sales, by Product Group & Region, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other) & (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
Chapter 3: Market Environment & Analysis
Overview
Demographic Patterns
Total Population
Population Aged 65 Years & Older
World Healthcare Trends
Health Expenditures
Hospitals
Physicians
Patient Activity
Hospital Admissions
Surgical Procedures
Outpatient Consultations
Table 3-1: Global Demographic & Healthcare Indicators, 2022-2031 (World Population, Healthcare Expenditures, Healthcare Resources, and Healthcare Activity)
Global Economic Climate
Biomarker Technologies
The Rising Role of AI and Machine Learning in Biomarker Analysis
Biomarker Market Analysis
Key Market Trends
Biomarker Product Markets
Table 3-2: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
Figure 3-2: Global Biomarker Share, by Product Group, 2025 vs. 2031 (%) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
Geographical Markets
Table 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific (China, Japan, Other), Central & South America, Eastern & Western Europe, North America (U.S., Canada, Mexico))
Figure 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
Figure 3-4: Global Biomarker Share, by Region, 2025 vs. 2031 (%) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
Chapter 4: Infectious Disease Biomarkers
Overview
Infectious Disease Biomarker Technologies
Key Biomarkers for Infectious Disease
Respiratory Diseases
Table 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
Figure 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
Figure 4-2: Global Respiratory Disease Biomarker Share, by Condition, 2025 (%)
Table 4-2: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
Figure 4-3: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
Figure 4-4: Global Respiratory Disease Biomarker Share, by Technology, 2025 (%) (Laboratory Immunoassay, Molecular, POC)
COVID-19
Pneumonia
Influenza
Group A Streptococcus Infections
Tuberculosis
Other Respiratory Infections
Healthcare-Associated Infections (HAIs)
Clostridioides difficile (c. diff)
Sepsis
Staphylococcus aureus
Enterococcus
Other Healthcare-Associated Infections
Table 4-3: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
Figure 4-5: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
Figure 4-6: Global Healthcare-Associated Infections (HAIs) Biomarker Share, by Type, 2025 (%) (C. diff, Enterococci, Sepsis, Staph, Other)
Hepatitis
Table 4-4: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
Figure 4-7: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
Figure 4-8: Global Hepatitis Biomarker Share, by Type, 2025 (%) (Hepatitis B, Hepatitis C, Other Types)
HIV
Table 4-5: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
Figure 4-9: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
Figure 4-10: Global HIV Biomarker Share, by Technology, 2025 (%) (Immunoassay, Molecular, Rapid POC)
Sexually Transmitted Diseases (STDs)
Human Papillomavirus (HPV)
Chlamydia/Gonorrhea (CT/NG)
Trichomoniasis
Herpes Simplex Virus (HSV-1 & HSV-2)
Other Sexually Transmitted Diseases
Syphilis
Balanitis
Chancroid
Molluscum Contagiosum
Pelvic Inflammatory Disease (PID)
Pubic Lice
Scabies
Vaginitis
Table 4-6: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
Figure 4-11: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
Figure 4-12: Global STD Biomarker Share, by Type, 2025 (%) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
TORCH
Table 4-7: Global TORCH Biomarker Sales, 2022-2031 ($ million)
Figure 4-13: Global TORCH Biomarker Sales, 2022-2031 ($ million)
Other Infectious Diseases
Malaria
Lyme Disease
H. pylori
Dengue
All Other Disease Biomarkers
Chagas Disease
Cyclosporiasis
Cysticercosis
Ebola
Hantavirus
Ringworm
West Nile Virus (WNV)
Zika Virus
Sales of Other Infectious Disease Biomarkers
Table 4-8: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
Figure 4-14: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
Figure 4-15: Global Other Infectious Disease Biomarker Share, by Type, 2025 (%) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
Market Analysis
Table 4-9: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
Figure 4-16: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
Figure 4-17: Global Infectious Disease Biomarker Share, by Major Product Group, 2025 (%) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
Table 4-10: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
Figure 4-18: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
Figure 4-19: Global Infectious Disease Biomarker Share, by Technology, 2025 (%) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
Biomarker Product Suppliers
Chapter 5: Cancer Biomarkers
Overview
Key Biomarkers for Cancer
Table 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
Figure 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
Figure 5-2: Global Cancer Biomarker Share, by Type, 2025 (%) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
Recent Developments
Predictive Biomarker Tests for Drug-Gene Match
Pharmacodiagnostic Tests
Precision Cancer Therapy
Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
Circulating Tumor Cell (CTC) Tests
Exosome Sequencing
Next-Generation Sequencing Tests
Market Analysis
Table 5-2: Global Cancer Biomarker Sales, by Condition, 2022-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
Figure 5-3: Global Cancer Biomarker Sales, by Condition, 2025-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
Figure 5-4: Global Cancer Biomarker Share, by Condition, 2025 (%) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
Biomarker Product Suppliers
Chapter 6: Cardiovascular Biomarkers
Overview
Key Biomarkers for Cardiovascular Conditions
Recent Developments
High-Sensitivity Troponins (hs-cTn)
Natriuretic Peptides (BNP/NT-proBNP)
Inflammatory Biomarkers
Metabolic and Lipid-Related Biomarkers
Emerging Biomarkers and Multi-Omics Approaches
Integration of AI and Machine Learning
Market Analysis
Table 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
Figure 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
Figure 6-2: Global Cardiovascular Biomarker Share, by Product Group, 2025 (%) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
Biomarker Product Suppliers
Chapter 7: Clinical Chemistry Biomarkers
Overview
Key Biomarkers for Clinical Chemistry
Electrolytes and Blood Gases
Urinalysis
Workstation Immunoassay Tests
Thyroid Testing
Fertility and Other Biomarkers
Recent Developments
Market Analysis
Table 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
Figure 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
Figure 7-2: Global Clinical Chemistry Biomarker Share, by Product Group, 2025 (%) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
Biomarker Product Suppliers
Chapter 8: Neurological Biomarkers
Overview
Key Biomarkers for Neurological Conditions
Recent Developments
Revolution in Alzheimer's Disease Blood Tests
Advances in Traumatic Brain Injury (TBI) Biomarkers
